Grants for Small businesses - Science and Technology

This funding opportunity supports innovative research and public engagement projects that explore the intersections of science, philosophy, and spirituality, targeting charitable organizations and individuals worldwide.

The Rural Child Care Planning Program seeks to support the use of data and analysis by rural communities to determine the specific needs and solutions for child care in their area. Donor Name: Iowa Economic Development Authority (IEDA) State: Iowa County: All Counties Type of Grant: Grant Deadline: (mm/dd/yyyy) 08/30/2024 Size of the Grant: $10,000 to $100,000 Grant Duration: 2 Years Details: Child care is a challenge across rural communities in Iowa and across the nation. However, the solutions are often more complicated than the construction of a new facility. Many factors need to be carefully analyzed to determine the feasibility for development of a child care center, expansion of an existing one or support for in-home providers. Through greater understanding of their geographic market, demographics, competition, financials, and other factors, communities can be armed with the information needed to take proactive steps towards addressing child care challenges. Funding from the program will empower communities to assess their current child care environment and develop strategies. The program, defined in Iowa Administrative Code, is administered by the Center for Rural Revitalization, a division of the Iowa Economic Development Authority (IEDA), in consultation with the Governor’s Empower Rural Iowa Initiative Task Forces. Funding Information Grant Recipients will be awarded $20,000. Grant Period All project activities and incurred expenses must occur within the eligible contracted funding period of October 1, 2024 – June 30, 2026. Uses of funds  The program provides funding for planning initiatives addressing child care needs through a professional third party partner. Eligible Project Requirements Requirements for Rural Child Care Planning Grant awards include, but are not limited to the following: Applicants must demonstrate the capacity for grants administration. Applications must provide 1:1/2 cash match. Applications must agree to contract with a professional third-party partner for completion of the market study and strategic goals. Applicant communities must identify the third-party organization in their application that will conduct the planning process.  Eligibility Criteria Iowa businesses, colleges and universities, city or county government, federally tax-exempt nonprofit agencies and foundations Projects/programs must exist in and benefit a community in Iowa with a population of 20,000 or fewer and not contiguous to a city with a population of 40,000 or greater. If a countywide project, must be in one of the 88 least populous counties. For more information, visit IEDA.

The Arizona Water Protection Fund (AWPF) is a competitive state grant program that provides funding to interested parties for the development and implementation of measures to protect water of sufficient quality and quantity to maintain, enhance, and restore river and riparian resources throughout Arizona (including projects that benefit fish and wildlife that are dependent on these important resources), and measures to increase water availability and supply. Financial Notes: Matching funds are not required to be eligible for AWPF funding; however, projects that do include matching funds typically receive higher consideration.   Administrative costs must be limited to a maximum of 5% of the total AWPF project funds requested.  Subcontractors or consultants working on your project must also conform to the 5% administrative cost limit if you are paying them out of AWPF funds.   Payments are made on a cost reimbursement basis.  Appropriate documentation (e.g., receipts, invoices, reports, data, and photographs) will be required in order to receive reimbursement.   Adequate accounting practices and record keeping will be required.

The Chautauqua County Department of Planning and Development in New York is offering a matching grant of $10,000 to $100,000 for a duration of 3 years to not-for-profit organizations, schools, governmental agencies, businesses, and landowners for the development of tourism events and attractions, with a focus on increasing visibility and visitor numbers.

Roanoke County Economic Development Authority’s Business Equipment Acquisition Program (BEAP) Grant offers funding opportunities for eligible for-profit businesses that desire to bolster their operations through the acquisition of new capital. Donor Name: Roanoke County Economic Development Authority State: Virginia County: Roanoke County (VA) Type of Grant: Grant Deadline: (mm/dd/yyyy) 09/01/2024 Size of the Grant: $10,000 to $100,000 Grant Duration: Grant Duration Not Mentioned Details: Funding Information The Authority will award grants of up to 50% of capital acquisition costs in amounts up to $20,000 per award. Eligible Acquisitions Eligible capital acquisitions must be taxable, pursuant of the Roanoke County Code, as business personal property or business machinery or tools. Examples include: Tangible Personal Property such as furniture, fixtures, office and business machines, tools and equipment used in any business or profession. Computer Equipment Only. Does not include software. Includes computer equipment, printers, disk drives, mouse, modem, etc. Machinery & Tools used in manufacturing, mining, processing, broadcasting, dry cleaners, commercial laundry, and dairy businesses. Eligibility Criteria In order to qualify for an award, a business must:  Employ more than three (3) full-time employees (or FTEs) at a physical location in Roanoke County, Have operated as a for-profit business for at least one year in Roanoke County,  Have a current County or town business license and be in good standing with all applicable requirements, and Have been and continue to be in compliance and in good standing with all local ordinances, on the County tax rolls, current with Roanoke County taxes/fees or other assessments, and have a current business license as required. For more information, visit Roanoke County Economic Development Authority

The Travel Oregon City grant program invites applications from non-profit and for-profit organizations to fund public events that attract tourists, support local businesses, and enhance the community's tourism brand, with a focus on transparency, financial stability, visitor attendance estimation, vendor involvement, and annual application for funding.

This funding provides financial support to build free broadband networks for low-income communities, including public housing and mobile home parks, ensuring residents have access to high-quality internet service.

The Miami Downtown Development Authority has launched the 2024-2025 Downtown Creative Collaborators Grants. Donor Name: Miami Downtown Development Authority State: County: All Counties Type of Grant: Grant Deadline: (mm/dd/yyyy) 08/19/2024 Size of the Grant: $10,000 to $100,000 Grant Duration: 1 Year Details: The Downtown Creative Collaborators Grant (DCCG) program is designed to support projects/events in FY2024-2025 that take place in Downtown Miami. The DCCG program will include innovative projects/events that should have a demonstrable economic impact in Downtown Miami while also strengthening its appeal as a global destination.  Funding Priorities Outdoor Venue – activating public spaces, green spaces, and unique open-air venues, for example, a rooftop, Miami Worldcenter, or city park that promotes Downtown Miami’s outdoor options. Community Building Opportunities – events/programs that promote and connect the Downtown community and attracts tourism.  Family Programming – events/activations that promote and provide programming suitable for the entire family to enjoy at an affordable ticket price point. Content that features the communities, history &/or natural resources in Miami-Dade is encouraged.  Programming Featuring Miami as a Global City – promotes Downtown Miami as an international and diverse cultural center, a culinary destination, and an innovation hub. Cultural and Historic Education – featuring Downtown’s historic story &/or buildings. Content highlights Downtown’s thriving art, culture, and entertainment community Public Transportation Awareness – build ridership and awareness of Downtown Miami’s multimodal transportation options through the event location and/or event marketing of Downtown’s diverse transportation options. Free or Discounted Projects/Events – Cost of admission/affordability is considered for grant funding. Free or discounted admissions for area residents, families, and students will receive funding priority. This must be clearly and visibly stated in marketing and promotional material when applicable.  Funding Information  Grant awards can range from $5,000.00 up to $50,000.00. The project/event’s activation must take place during the grant fiscal year (Oct 1, 2024 – Sept 30, 2025).  Eligibility Criteria  The Miami DDA values organizations producing and implementing multiple activations Downtown. For an application to be considered, it must meet the following requirements:   The applicant must have a reputation of professional and personal excellence and conduct. *All felonies &/or misdemeanors must be disclosed on the application. The applicant must submit documentation of having produced the activation in the past or a similar program. If this is the applicant’s first public activation, a comprehensive and detailed business plan needs to be submitted.  The applicant must provide a confirmation letter or a letter of intent from the event venue confirming dates and times for the activation. Timelines for the activation must include all stages of the project/event including pre-marketing, live event, and wrap-up/post-event.  If the project/event requires permitting from the City of Miami, Miami-Dade County, or approval from Bayfront Park, you are required to provide a copy of either the submitted permit application or an approved permit with your application. The applicant organization must be an active corporation in good standing as a “for profit” or “not-for-profit.” Visit Sunbiz to check your business status. The applicant must provide proof of funding commitments from other sources. The Miami DDA’s DCCG cannot be the only funding source for your project/event.  For more information, visit Miami DDA.

The Roddenberry Prize is a $1 million grant awarded to early-stage scientific or technology ventures using AI and machine learning to contribute to a more equitable and prosperous world, with a focus on solutions that align with the United Nations Sustainable Development Goals.

The DoD Reconstructive Transplant Research Investigator-Initiated Research Award is a funding opportunity aimed at supporting innovative and impactful research projects that contribute to reconstructive transplant science, improve patient care, and enhance the quality of life, with a particular focus on addressing the healthcare needs of military service members, veterans, and their families.

The DoD Reconstructive Transplant, Idea Discovery Award is a funding opportunity aimed at supporting innovative, high-risk/high-reward research projects related to reconstructive transplant, with a focus on generating robust data, addressing military health care needs, advancing women's health research, and adhering to rigorous experimental design, with a total budget not exceeding $500,000.

The Alliance for Pediatric Device Innovation (APDI) is offering grants up to $50,000 for pediatric medical devices aimed at improving the monitoring, diagnosis, or treatment of youth substance use disorders and addiction. Up to $150,000 in total grant funds are available for distribution. Eligible applicants include inventors from established businesses, startups, and academic researchers with commercializable device concepts that address unmet pediatric needs. The goal is to support the development of devices that can be commercialized, with an emphasis on bridging the gap between prototyping and FDA approval, marketing, and sales. Proposals should focus on innovations such as AI-based diagnostic tools, digital therapeutics, wearable devices, and neuromodulation therapies. The application deadline is July 30, 2024, and winners will be announced on August 15, 2024.

This grant provides funding for innovative research proposals from universities, non-profits, and businesses to develop disruptive technologies that enhance the U.S. Army's capabilities for future operations.

The Academy of Kidney Cancer Investigators (AKCI) is a unique, interactive virtual academy that provides, intensive mentoring, national networking, and a peer group for scientist and clinician junior faculty. The KCRP created the Academy of Kidney Cancer Investigators in FY19 to align with several program priorities, which include to build research capacity in kidney cancer; increase collaborations to advance kidney cancer research, and support innovative research conducted by the next generation of kidney cancer scientists and clinicians. The overarching goal of the AKCI is to increase research capacity in kidney cancer through the development of successful, highly productive kidney cancer researchers in a collaborative research and training environment. The AKCI is a virtual career development and research training platform that currently consists of 11 Early-Career Scholars (ECS)/Designated Mentor pairs from different institutions, and one Academy Director. It is expected that six Early-Career Scholars will graduate by the fall of 2025 and four FY23 AKCI Early-Career Scholars/Designated Mentor awards will be made by September 2024. In addition, Academy graduates will continue to participate in the annual Academy meetings. Information about the Academy is available on the KCRP webpage and in the Kidney Cancer Program Booklet at https://cdmrp.health.mil/kcrp. The AKCI leadership team will identify opportunities for engagement with KCRP AKCI Scholars-Designated Mentors and KCRP FY25 (and subsequent year awardees) Postdoctoral and Clinical Fellowship Awardees. The Academy Director and Deputy Director catalyze the growth and professional development of the Early-Career Scholars in collaboration with their Designated Mentors, assess the progress of the ECSs, and facilitate communication and collaboration among all of the Academy members. The AKCI leadership team will also identify and offer opportunities for engagement (e.g., invitations to seminar series and in-person meetings) with FY24 Postdoctoral and Clinical Fellowship Awardees with FY24 KCRP AKCI-ECS-Designated Mentors (and subsequent year awardees). This FY24 funding opportunity is soliciting applications for an Academy Director (Principal Investigator [PI]) and Deputy Director (Partnering PI) to lead the AKCI. The newly selected FY24 Academy Director and Deputy Director will initiate their responsibilities no later than October 2025. The Academy Director and Deputy Director (hereafter referred to as Academy Leadership) must be established kidney cancer researchers and can be at different institutions. The Academy Leadership must demonstrate a strong record of mentoring and training early career investigators, a commitment to leadership, the ability to articulate methods toward research collaborations, and the ability to objectively assess the progress of all Scholars with their Designated Mentors in the AKCI. Other objectives will include execution of research that will engage AKCI FY24 Scholars (including subsequent-year Scholars), develop tools for Scholars to enable success, and provide opportunities to broaden their knowledge in kidney and renal pelvis cancers. The leadership team will identify and offer occasion(s) for the AKCI to network with KCRP FY24 Postdoctoral and Clinical Fellowship Awardees (and subsequent year awardees). Designated Mentors on FY24 KCRP AKCI Early-Career Scholar Award applications and Designated Mentors on open FY19 through FY23 KCRP AKCI Early-Career Scholar Awards (with the exception of those graduating in 2024) are not eligible to apply for this award. Note: An invited oral presentation is a requirement for application review of the KCRP AKCI LA, as described in Section II.D.2.b.iv, Additional Application Components. Responsibilities of the Academy Leadership include, but are not limited to: Act as a resource for all Scholars and Designated Mentors in the Academy over the Scholars 4-year period of performance. Facilitate communication and collaboration among all Scholars and Designated Mentors (including periodic interactive communication among all Academy members). Develop assessment criteria to evaluate the research progress made by all Scholars, as well as their career progression and sustainment as independent investigators in kidney cancer research. Conduct collaborative kidney cancer pilot project(s) that include Academy Scholars. These pilot projects should have the potential to improve collaboration within the Academy, as well as impact kidney cancer research and/or kidney cancer patients/survivors. o Examples of pilot research projects may include but are not limited to (a) funding an extended statistical or bioinformatics analysis with AKCI Scholars, (b) performing a large-scale meta-analysis of human or animal datasets with AKCI scholars, (c) provide access to critical biorepositories or animal models to expand AKCI investigator analyses or increase study rigor. Provide constructive critiques with the goal of advancing the research and professional careers of the Scholars and strengthening the mentorship of the Designated Mentors. Provide avenues to increase the promotion of the Academy and visibility of Scholars within kidney cancer research and advocacy communities (e.g., peer review, conferences, editorial boards). Support the professional development, to include laboratory management skills, of the Scholars into leading researchers through invited presentations by experts outside of the AKCI LA. Plan and host an annual 1-day workshop and, biennially, a multi-day workshop for all Scholars/Designated Mentor pairs as well as Academy graduates to present their research, share knowledge, and develop collaborative efforts within the AKCI. Scholars will be responsible for their own travel costs to in-person Academy meetings. Include KCRP FY24 Postdoctoral and Clinical Fellowship Awardees in at least one meeting of the FY24 AKCI. These investigators will be responsible for their own travel costs, funds for which are included in their research awards. Establish a panel of patient advocates and Veteran(s) (i.e., the Patient Advocacy Panel) to inform the AKCI on the needs of the patient community. Establish the Designated Mentor Panel to facilitate collaborations among the AKCI participants including the Scholars, Academy Director/Deputy Director, and the Designated Mentors. The Academy of Kidney Cancer Investigators Leadership Award is structured to support two PIs. The Academy Director will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The Deputy Director will be identified as the Partnering PI. The collaboration between the Academy Director and the Deputy Director should be supported by complementary expertise and experience. Initiating and Partnering PIs each have different submission requirements, as described in Section II.D.2, Content and Form of the Application Submission; however, both PIs should contribute significantly to the development of the proposed research project. The application should clearly demonstrate that both PIs have equal levels of input on the proposed Academy Leadership and clearly define the components to be addressed by each to support the success of the Scholars. While it is up to the Academy Director and the Deputy Director to define their roles, both Academy Leaders should have interactions with each Scholar-Designated Mentor pair, (and the Scholars Designated Mentors); acting as administrative support does not fulfill the intent of the Director and Deputy Director. If recommended for funding, each PI will be named on separate awards to the recipient organization(s). Each award will be subject to separate reporting, regulatory, and administrative requirements. For individual submission requirements for the Initiating and Partnering PI(s), refer to Section II.D.2, Content and Form of the Application Submission. Organizational-Level Emphasis: The following areas of emphasis are broadly applicable to many CDMRP programs, not just the KCRP. Investigators are encouraged to consider addressing these areas in their applications if doing so is appropriate for their line of research, addresses the FY24 KCRP strategic priorities and/focus areas described in Section II.A.1 and Section II.A.2. Nuclear Medicine: Innovative research involving nuclear medicine and related techniques to support early diagnosis, more effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies. Womens Health: CDMRP encourages research on health areas and conditions that affect women uniquely, disproportionately, or differently from men, including studies analyzing sex as a biological variable. Such research should relate anticipated project findings to improvements in womens health outcomes and/or advancing knowledge for womens health. Metastatic Cancer Task Force: A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 KCRP priorities. Rigorous Study Design: All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (https://www.nature.com/nature/journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies. Military Service Involvement: Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the U.S. Department of Veterans Affairs (VA), and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research. Clinical trials are not allowed under this funding opportunity. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes. Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials. For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes: (1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies. (2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. (3) Outcomes research and health services research that do not fit under the definition of clinical trial. Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule. The funding instrument for awards made under the program announcement will be cooperative agreements (31 USC 6305). Substantial CDMRP programmatic involvement with recipients is anticipated during the performance of award activities. Substantial involvement means that, after award, CDMRP staff will assist, guide, coordinate, or participate in project activities including but not limited to: Participating in the Steering Committee that oversees study conduct. Make recommendations for continued funding based on (a) overall study progress, including sufficient patient and/or data accrual; (b) cooperation in carrying out the research (e.g., attendance at Steering Committee meetings, implementation of group decisions, compliance with the terms of award and reporting requirements); and/or (c) maintenance of a high quality of research. The anticipated combined direct costs budgeted for the entire period of performance for a FY24 KCRP AKCI LA should not exceed $1,500,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information. Awards supported with FY24 funds will be made no later than September 30, 2025. The CDMRP expects to allot approximately $2.4M to fund approximately one KCRP Academy of Kidney Cancer Investigator Leadership Award application (consisting of an Initiating PI application and a Partnering PI application). Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 and FY26 funds, which will expire for use on September 30, 2030, and September 30, 2032, respectively.

The "Privacy-Preserving Data Sharing in Practice" grant aims to fund research and development projects that create practical, scalable technologies for sharing data in a way that preserves privacy, with a focus on advancing privacy-enhancing technologies for artificial intelligence, developing tools and testbeds for safe data sharing, and promoting the usability and inclusiveness of these solutions.

The FY24 KCRP Concept Award supports highly innovative, untested, potentially groundbreaking novel concepts in kidney cancer. The Concept Award is not intended to support an incremental progression of an already established research project but, instead, it allows Principal Investigators (PIs) the opportunity to pursue serendipitous observations. Preliminary data are not allowed and should not be discussed. This award mechanism supports high-risk studies that have the potential to reveal entirely new avenues for investigation. Applications must describe how the new idea will enhance the existing knowledge of kidney cancer or develop an innovative and novel course of investigation. Research completed through a Concept Award may generate sufficient preliminary data to enable the PI to prepare an application for future research.Organizational-Level Emphasis Areas:The following areas of emphasis are broadly applicable to many CDMRP programs, not just the KCRP. Investigators are encouraged to consider addressing these areas in their applications if doing so is appropriate for their line of research, addresses the FY24 KCRP strategic priorities and/or focus areas described in Section II.A.1 and Section II.A.2.Nuclear Medicine: Innovative research involving nuclear medicine and related techniques to support early diagnosis, more effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies.Womens Health: CDMRP encourages research on health areas and conditions that affect women uniquely, disproportionately, or differently from men, including studies analyzing sex as a biological variable. Such research should relate anticipated project findings to improvements in womens health outcomes and/or advancing knowledge for womens health.Metastatic Cancer Task Force: A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 KCRP priorities.Rigorous Study Design: All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (https://www.nature.com/nature/journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies.Military Service Involvement: Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the U.S. Department of Veterans Affairs (VA), and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.Reviewers will be blinded to the identity of the Principal Investigator (PI), collaborator(s), and their organization(s). Refer to Section II.D.2.b.i, Full Application Guidelines, for more information.Clinical trials are not allowed under this funding opportunity.A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated direct costs budgeted for the entire period of performance for an FY24 KCRP Concept Award should not exceed $100,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $1.44M to fund approximately nine Concept Award applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

This funding opportunity supports educational projects that enhance training for technicians in high-technology fields, particularly at two-year colleges, while fostering partnerships with industry and addressing workforce needs.

Amendment 1 (June 25, 2024): The purpose of this Amendment 1 is to: 1) make administrative updates to Section 1.1, 1.2, 2.1.2, 3.1, 3.2 and 5.2.6; 2) replace Section 2.1.1 with new language pertaining to Federally Funded Research and Development Centers (FFRDCs) and Government Entities. Additionally, Section 4.2, Evaluation Criteria #2 is updated to remove the reference to Government Entities (removal is not highlighted in yellow); 3) change references from Abstract to Solution Summaries (intent behind the document is unchanged); 4) update proposal submission instructions in Section 3.2; and 5) update Section 5.1 to remove the Stage 2 Notification Letter. All changes are highlighted in yellow.Also, please note that the title of this opportunity has bee revised to eliminate confusion. The opportunity should have been titled, "Master Announcement Instruction (MAI)" instead of "ARPA-H BDF Tool Box".The Master Announcement Instructions (MAI) is a new ARPA-H announcement that aims to create standard tiered proposal submission requirements, so the amount of work required to write a proposal is commensurate with the size of the proposed effort. It also aims to reduce the up-front work required to submit cost information to reduce the barrier to entry for non-traditional performers. Module announcements that link to this MAI will provide more specific instructions about how the proposal requirements vary across tiers of effort.All responsible sources capable of satisfying the Governments needs may submit a proposal to a Module Announcement. Specifically, universities, non-profit organizations, small businesses and other than small businesses are eligible and encouraged to propose to Module Announcements.NOTE: Proposals shall NOT be submitted against the MAI. Proposals shall only be submitted against a Module Announcement.

This program provides funding and support to Massachusetts-based startups that have received Phase II SBIR or STTR awards, helping them commercialize their technologies and cover expenses like prototyping, patenting, and market research.

The Pennsylvania Department of Environmental Protection is seeking applications for its Alternative Fuels Incentive Grants. Donor Name: Pennsylvania Department of Environmental Protection State: Pennsylvania County: All Counties Type of Grant: Grant Deadline: (mm/dd/yyyy) 06/28/2024 Size of the Grant: $10,000 to $100,000 Grant Duration: Grant Duration Not Mentioned Details: AFIG has approximately $5 million in funding available to school districts, municipalities, nonprofit organizations, and businesses in Pennsylvania that want to transition to cleaner fuel transportation. Supported alternative fuels include electricity, compressed natural gas, liquefied natural gas, propane, hydrogen, hythane, biodiesel, ethanol, methanol, and other advanced biofuels. Grant funding covers: Incremental costs related to retrofitting vehicles to operate on alternative fuels; Incremental costs to purchase alternative fuel vehicles; Cost to purchase and install the necessary fleet-refueling or home-refueling equipment for alternative fuel vehicles; Cost to perform research, training, development, and demonstration of new applications or next-phase technology related to alternative fuel vehicles. Priorities Businesses whose headquarters or principal place of business are located in Pennsylvania; Zero emission vehicle projects; Medium-duty and light-duty fleet refueling infrastructure projects; Renewable natural gas vehicle and infrastructure projects; Projects located in or predominantly serving environmental justice areas; Minority-, veteran-, or woman-owned businesses. Funding Information Applicants will be eligible for a maximum grant award across all applications of $500,000. Individual application awards are still capped at $300,000. Eligibility Criteria DEP will award at least 20% of AFIG funding to the following entities, depending on applications received: Counties, townships, municipalities, or municipal authorities; Public school districts, including brick and mortar charter schools; Organizations registered as a 501(c)3 that provide services to seniors, low-income individuals and families, individuals with disabilities, veterans, or medical services of any type; Businesses that are registered with the Commonwealth as a Small Diverse Business or registered with one of the Pennsylvania Department of General Services approved third-party certifications; and Organizations that are county/local government supported or contracted to provide services to seniors, low-income individuals and families, individuals with disabilities, veterans, or medical services of any type. For more information, visit DEP.